AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 701072
Drug: Lioresal (antispasticity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lioresal (antispasticity drug)
Trial: 11295008
Drug: Hospital outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital outpatient clinic injections by medical staff
Trial: 11295008
Drug: Home injections
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home injections by the nurse practitioner
Trial: 9047153
Drug: sTNFR:Fc therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sTNFR:Fc therapy
Trial: 8451040
Drug: Oral medium-dosed
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medium-dosed metoclopramide (MCL, 3.5 mg/kg b.w./cycle)
Trial: 3530049
Drug: Intravenous lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine, 1.5 mg/kg, administered 2 minutes before laryngoscopy and intubation
Trial: 18308741
Drug: Terlipressin 1
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin 1 mg
Trial: 18308741
Drug: Terlipressin 1
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin 1 mg followed by dobutamine infusion titrated to reverse the anticipated reduction in Svo2
Trial: 1508058
Drug: Oestriol (E3)
RxNorm normalized name: Oestriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestriol (E3) 0.5 mg administered intravaginally daily for 2 weeks, then once or twice weekly for 4 weeks as maintenance dose.
Trial: 24118972
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily PTNS
Trial: 24118972
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly PTNS
Trial: 15204160
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream plus PUVA therapy
Trial: 11264634
Drug: Nystatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin (5 mL oral suspension, four times daily)
Trial: 11264634
Drug: Clotrimazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (10 mg troche, three times daily)
Trial: 26673560
Drug: Polypharmacy (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (≥ 10 medications)
Trial: 18664560
Drug: Clodronate 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1600 mg/day for 2 years
Trial: 12719503
Drug: Nurse-administered Structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered Structured Clinical Interview for DSM-IV-Clinician Version (SCID)
Trial: 7490838
Drug: 8 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 months of reversible androgen ablation therapy
Trial: 1586932
Drug: Enalapril (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (3 months therapy)
Trial: 20410252
Drug: Additional psychological
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional psychological treatment (written information on medical and psychological consequences of an ICD plus 6 months of individual phone counseling)
Trial: 20410252
Drug: Additional psychological
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional psychological treatment
Trial: 18509656
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 100 mL of 300 mg I/mL at 5.0 mL/s
Trial: 18509656
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 100 mL of 300 mg I/mL at 3.5 mL/s
Trial: 18509656
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: 100 mL of 350 mg I/mL at 3.5 mL/s
Trial: 12204703
Drug: 0.005% latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% latanoprost once daily (n = 737)
Trial: 12204703
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol twice daily (n = 652)
Trial: 8739541
Drug: Pentoxifylline 600
RxNorm normalized name: pentoxifylline 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 600 mg intravenously twice a day
Trial: 10482146
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus cilostazol
Trial: 17949573
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment by family doctors unaware of the guideline
Trial: 17949573
Drug: Clinical practice
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical practice guideline treatment
Trial: 23388530
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment
Trial: 11866684
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (control group)
Trial: 22357255
Drug: Nilotinib 400
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400 mg b.i.d.
Trial: 20353107
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Sparfloxacin tablets and Prostat tablets); oral administration
Trial: 15841494
Drug: Mobicox (meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobicox (meloxicam 7.5 mg)
Trial: 3266333
Drug: Bromocriptine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine therapy
Trial: 359925
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of Rifampicin daily for 3 months
Trial: 30919998
Drug: EA-230 (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA-230 (15, 45 and 90 mg/kg/h)
Trial: 24190844
Drug: Individual adolescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual adolescent focused therapy (AFT)
Trial: 8431119
Drug: Cimetidine continuous
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine continuous infusion
Trial: 3582476
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 and 650 mg)
Trial: 6088252
Drug: Triprolidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine (10 mg)
Trial: 31558010
Drug: Proxelan® monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxelan® monotherapy (1 suppository at bedtime for 1 month)
Trial: 29153295
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of saline (placebo group, n=48)
Trial: 23245940
Drug: Calendula cream
RxNorm normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calendula cream
Trial: 3900155
Drug: 3% topical
RxNorm normalized name: Triaz 3% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% topical minoxidil
Trial: 29908389
Drug: Prediction tool
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction tool based on well-established risk factors (number of previous depressive episodes, residual depressive symptoms, severity of the last depressive episode, treatment)
Trial: 26867060
Drug: Olmesartan 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20-40 mg/Amlodipine 5-10 mg
Trial: 26867060
Drug: Perindopril 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4-8 mg/Amlodipine 5-10 mg
Trial: 17874207
Drug: Atomoxetine (detailed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (detailed dosage not specified)
Trial: 11939055
Drug: Selenium (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (1 mg sodium selenite, one time only)
Trial: 19257818
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg) administered within 90 days after surgical repair of an osteoporotic hip fracture
Trial: 11564611
Drug: Sham water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham water treatment units (WTUs).
Trial: 7820981
Drug: Somatostatin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin, 100 micrograms subcutaneously at induction of anaesthesia and 8 hourly for 48 h
Trial: 3078526
Drug: no analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no analgesic supplement
Trial: 29217669
Drug: 930 mg
RxNorm normalized name: PETROLATUM 930 mg in 1 g TOPICAL OINTMENT [Vitamins A and D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 930 mg choline/d
Trial: 29217669
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg choline/d
Trial: 19327776
Drug: On-treatment apolipoproteins
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment apolipoproteins A1 and B
Trial: 19327776
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering treatment
Trial: 19327776
Drug: Usual-dose simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual-dose simvastatin
Trial: 27815148
Drug: Conditional cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditional cash transfer (monthly cash transfer conditional on school attendance ≥80% of school days per month)
Trial: 23179896
Drug: Olmesartan 10
RxNorm normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 10 mg (up-titrated to 20 mg or 40 mg if needed)
Trial: 23179896
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg (up-titrated to 5 mg or 10 mg if needed)
Trial: 7617626
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus electrophoresis and UV blood irradiation (group 1)
Trial: 8471816
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (group 2)
Trial: 7617626
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (group 1)
Trial: 2651492
Drug: PPA 75
RxNorm normalized name: Guaifenex PPA 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 75 mg sustained release
Trial: 2387651
Drug: PPA 25
RxNorm normalized name: APAP 650/CTM 4/PPA 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 25 mg
Trial: 30547316
Drug: F14512 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F14512 at dose level 10 mg/m2/day
Trial: 28855568
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rGH)
Trial: 21462059
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Therapy (PST), 1 to 8 sessions, 45 minutes each with a social worker
Trial: 9495423
Drug: Dextromethorphan 30
RxNorm normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 30 mg
Trial: 8346588
Drug: Salcatonin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salcatonin (any dose)
Trial: 29718143
Drug: Colistin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin monotherapy and colistin-carbapenem combination EAT
Trial: 29718143
Drug: Covering antibiotics
RxNorm normalized name: Canker Cover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covering antibiotics in propensity score-matched cohort (n = 338)
Trial: 24344211
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (IFN‐α‐2b) 20 MIU/m(2) intravenously (IV) daily 5 days per week for 4 weeks (arm A)
Trial: 22987303
Drug: Water (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (100 ml three times daily)
Trial: 22987303
Drug: Coffee (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee (100 ml three times daily)
Trial: 8697293
Drug: Idazoxan (295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (295 μg/kg)
Trial: 6319151
Drug: ACTH 1‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 7.00 h in winter
Trial: 6319151
Drug: ACTH 1‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 14.00 h in summer
Trial: 25645168
Drug: Delayed-treatment waitlist
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment waitlist control group
Trial: 22185621
Drug: ALC (alcoholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALC (alcoholic beverage containing 1 g·kg(‐1) body weight)
Trial: 18510263
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 800 mg on day 3)
Trial: 18510263
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (600 mg/day and 800 mg/day)
Trial: 197444
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg i.m. ACTH4-10
Trial: 22341380
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of hypertonic saline before airway clearance techniques
Trial: 22341380
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of hypertonic saline during airway clearance techniques
Trial: 22341380
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of hypertonic saline after airway clearance techniques
Trial: 2328310
Drug: Half-strength formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-strength formulation (25 mg hydrochlorothiazide and 37.5 mg triamterene)
Trial: 2328310
Drug: Full-strength formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength formulation (50 mg hydrochlorothiazide and 75 mg triamterene)
Trial: 23127304
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point pressure release therapy (TPPRT)
Trial: 14692928
Drug: Intralesional 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional 5-fluorouracil (5-FU) at weekly intervals for 12 weeks
Trial: 10480608
Drug: Homeostasis model
RxNorm normalized name: CALCIUM HOMEOSTASIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeostasis model assessment (HOMA) using immunoreactive insulin
Trial: 10480608
Drug: First-phase intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-phase intravenous glucose tolerance test (FSIVGTT)
Trial: 8942885
Drug: Topical metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical metronidazole applied to the lid margin in one eye
Trial: 30167782
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day adjunctive raloxifene
Trial: 25302927
Drug: GOS-supplemented formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS-supplemented formula (0.4 g/100 mL)
Trial: 22689395
Drug: Topical microemulsion
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical microemulsion containing metronidazole
Trial: 22689395
Drug: Commercial gel
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial gel product
Trial: 30970056
Drug: Homeopathic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic therapy (including Berberis, Mercurius solubilis/Belladonna/Hepar sulphur, and Pyrogenium)
Trial: 30970056
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy (NSPT) + Homeopathic therapy
Trial: 29974280
Drug: He-Ne laser
RxNorm normalized name: Ne
DrugBank: Neon (DB11589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: He-Ne laser and topical treatment
Trial: 24699061
Drug: Losmapimod (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod (7.5 mg BD) for 6 weeks
Trial: 19560322
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release (ER) 3, 6, 9, or 12 mg
Trial: 17761460
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with dutasteride and tamsulosin
Trial: 17761460
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with dutasteride
Trial: 17761460
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with tamsulosin
Trial: 6233150
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) 20 mg twice a day for 2 weeks, then aminoglutethimide (AG) 250 mg four times a day
Trial: 16329060
Drug: Placebo (subconjunctival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subconjunctival injection), repeated after 2 months
Trial: 12547661
Drug: 20-mcg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mcg oral contraceptive (OC)
Trial: 2687691
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 0.07 U/kg body weight, subcutaneously at bedtime
Trial: 4629980
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (D.S.C.G.)
Trial: 24326106
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg) guided by visual acuity stabilization criteria (group I)
Trial: 24326106
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg) (group I)
Trial: 24326106
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg) (group II)
Trial: 24326106
Drug: Verteporfin photodynamic
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin photodynamic therapy (vPDT) (group III)
Trial: 19664345
Drug: Oral mefenamic
RxNorm normalized name: meclofenamate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mefenamic acid and intramuscular meperidine (M&M)
Trial: 12744480
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) at 0.05 mg/kg/day
Trial: 1784030
Drug: Ribavirin therapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin therapy (200 mg four times a day)
Trial: 7223696
Drug: Maternal education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal education program without nutritional supplement
Trial: 31551213
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 50,000 IU weekly for 12 weeks
Trial: 28396556
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for STIs during pregnancy (control group)
Trial: 22287681
Drug: Dried distillers
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried distillers grains (DDG) supplement
Trial: 8462537
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nicomorphine
Trial: 8462537
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nicomorphine
Trial: 8462537
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nicomorphine
Trial: 7955553
Drug: Cortisol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol treatment
Trial: 30828929
Drug: BioChaperone glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BioChaperone glargine lispro co-formulation (BC Combo)
Trial: 28482406
Drug: Endoscopic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapy (2-3 times)